Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ambrx Biopharma (AMAM)
NASDAQ:AMAM
Holding AMAM?
Track your performance easily
See the Price Targets and Ratings of:
AMAM Analyst Ratings
Hold
0 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AMAM Stock 12 Month Forecast
Average Price Target
$28.00
▲(0.00% Upside)
| Highest Price Target$28.00 | Average Price Target$28.00 | Lowest Price Target$28.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Robert W. Baird
Downgraded
01/16/24
JMP Securities
Downgraded
01/10/24
RBC Capital
Downgraded
01/08/24
BTIG
Downgraded
01/08/24
B.Riley Financial
Downgraded
01/08/24
Goldman Sachs
―
Hold
―
Reiterated
12/08/23
Goldman Sachs Keeps Their Hold Rating on Ambrx Biopharma (AMAM)
TD Cowen
―
Buy
―
Reiterated
11/21/23
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (NASDAQ: PSTV), Ambrx Biopharma (NASDAQ: AMAM) and Marinus (NASDAQ: MRNS)
Oppenheimer
$30
Buy
7.14%
Upside
Reiterated
10/21/23
The data in Ambrx’s poster (unveiled Saturday) looked even better than the abstract. Efficacy improved (with PSA50 now clearing the 50% hurdle). There were responses post-PLUVICTO, a clear dose-response, and actual tolerability. Yet as the former CAR-T team at Opco, this almost feels like dejà vu: Amgen unveils a secretive Bite program that wows the largely academic audience (and perhaps explaining abstract weakness?) Luckily for Ambrx, AMG 509 looks to us like a neat science experiment and not a commercial drug: Honestly, with 50% dose interruptions, how are investigators even allowed to call something "well tolerated" anymore? We digress. We think Ambrx is the real winner in prostate at ESMO. Reiterate Outperform; $30 PT.
Best Analysts Covering Ambrx Biopharma
Which Analyst Should I Follow If I Want to Buy AMAM and Sell After:
1 Month
xxx
Success Rate
2/3 ratings generated profit
Average Return
+7.67%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +7.67% per trade.
3 Months
xxx
Success Rate
2/3 ratings generated profit
Average Return
+84.27%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +84.27% per trade.
1 Year
Success Rate
3/3 ratings generated profit
Average Return
+136.53%
reiterated a buy rating a year ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +136.53% per trade.
2 Years
xxx
Success Rate
3/3 ratings generated profit
Average Return
+136.53%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +136.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AMAM Analyst Recommendation Trends
Rating
Sep 23
Oct 23
Nov 23
Dec 23
Jan 24
Strong Buy
9
10
12
9
6
Buy
1
2
5
5
4
Hold
1
1
2
2
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
13
19
16
17
Each month's total comprises the sum of three months' worth of ratings.
AMAM Financial Forecast
AMAM Stock Forecast FAQ
What is AMAM’s average 12-month price target, according to analysts?
Based on analyst ratings, Ambrx Biopharma’s 12-month average price target is $28.00.
What is AMAM’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for AMAM, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AMAM a Buy, Sell or Hold?
Ambrx Biopharma has a consensus rating of Hold which is based on 0 buy ratings, 5 hold ratings and 0 sell ratings.
What is Ambrx Biopharma’s price target?
The average price target for Ambrx Biopharma is $28.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $28.00 ,the lowest forecast is $28.00. The average price target represents 0.00% Increase from the current price of $28.
The highest analyst price target is $28.00 ,the lowest forecast is $28.00. The average price target represents 0.00% Increase from the current price of $28.
What do analysts say about Ambrx Biopharma?
Ambrx Biopharma’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of AMAM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.